Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group.

Abstract

The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial of interleukin-12 (IL-12) for plateau phase multiple myeloma. Patients were initially treated with IL-12 250 ng/kg I.V. daily for 5 days every 3 weeks. The trial was modified due to toxicity after the first 16 patients. IL-12 was given 300 ng/kg subcutaneously twice weekly for 24 weeks. Of 48 eligible patients, there were 4 objective responses (8.3%), all CR. The median survival and progression-free survival were 42.8 and 11.4 months. Unacceptable grade 3 or 4 non-hematologic toxicity (31% with IL-12 subcutaneously and 63% with IL-12 intravenously) was observed.

• Authors: Martha Q Lacy, Susanna Jacobus, Emily A Blood, Neil E Kay, S Vincent Rajkumar, Philip R Greipp
• Journal: Leukemia research (Leuk Res) Vol. 33 Issue 11 Pg. 1485-9 (Nov 2009) ISSN: 1873-5835 [Electronic] England
• PMID: 19243818 (Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Interleukin-12

Topics

• Adult
• Aged
• CD4 Lymphocyte Count
• Female
• Humans
• Interleukin-12 (adverse effects, therapeutic use)
• Male
• Middle Aged
• Multiple Myeloma (drug therapy, immunology)
• Survival Analysis
• T-Lymphocyte Subsets